Prosecution Insights
Last updated: July 05, 2026
Application No. 17/051,092

ESTERS AND ETHERS OF 3-METHYL-PENTANE-DIOL AND UNSATURATED DERIVATIVES THEREOF AND THEIR USE AS AROMA CHEMICAL

Final Rejection §112
Filed
Oct 27, 2020
Priority
Apr 27, 2018 — EU 18169757.4 +1 more
Examiner
ROBERTS, LEZAH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF A/s
OA Round
6 (Final)
49%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
85%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allowance Rate
371 granted / 762 resolved
-11.3% vs TC avg
Strong +36% interview lift
Without
With
+36.0%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
60 currently pending
Career history
836
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
77.8%
+37.8% vs TC avg
§102
3.9%
-36.1% vs TC avg
§112
2.1%
-37.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 762 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed December 31, 2025, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims Claim Objections Claims 3, 9 and 12-13 are objected to because of the following informalities: Claim 12 recites various fragrances where “and” are incorporated in several places where they not needed or appropriate. The “and” need to be removed. Claim 3 comprises typos. The phrase “features b) and/or c)” should read “features a) or b)”. Appropriate correction is required. Claim Rejections - 35 USC § 112 – Indefiniteness (Maintain Rejection) Claim 13 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 13 recites “selected from the group”. It is not clear if this is defining the composition, for example, the composition is product selected from the group; or if the composition comprises one of the group. Response to Arguments Applicant does not appear to address this rejection. It is suggested applicant amend the claim to recite “wherein the composition is selected from the group consisting of”. Allowable Subject Matter Claims 2-3, 9 and 12-13 are free prior art. Some of the withdrawn claims are subject to Rejoinder. It is suggested Applicant file amended claim in response to this Action with amended claims including legible/clear structures. Conclusion Claims 3, 9 and 12-13 are objected. Claim 13 is rejected. Claim 2 is allowed. Claims 7 and 14-23 are withdrawn. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LEZAH ROBERTS whose telephone number is (571)272-1071. The examiner can normally be reached Monday-Friday 11:00-7:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached on 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LEZAH ROBERTS/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Show 6 earlier events
Oct 10, 2024
Non-Final Rejection mailed — §112
Jan 10, 2025
Response Filed
Apr 24, 2025
Final Rejection mailed — §112
Jul 23, 2025
Request for Continued Examination
Jul 24, 2025
Response after Non-Final Action
Oct 02, 2025
Non-Final Rejection mailed — §112
Dec 31, 2025
Response Filed
May 04, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12661309
PREPARATION AND EFFICACY OF TOOTH WHITENING TABLET INCLUDING SHMP
5y 0m to grant Granted Jun 23, 2026
Patent 12594229
Personal Care Compositions and Methods for the Same
5y 2m to grant Granted Apr 07, 2026
Patent 12594241
TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF
2y 7m to grant Granted Apr 07, 2026
Patent 12582583
ORAL CARE PRODUCT COMPRISING AN ORAL CARE RHEOLOGICAL SOLID COMPOSITION
4y 11m to grant Granted Mar 24, 2026
Patent 12558387
MULTI-VIRUS ANTI-INFECTIVITY AND PRO-IMMUNITY ASSEMBLY
2y 2m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
49%
Grant Probability
85%
With Interview (+36.0%)
4y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 762 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month